Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review)
- Authors:
- Zexiong Gong
- Weiguo Huang
- Baiyun Wang
- Na Liang
- Songkai Long
- Wanjun Li
- Qier Zhou
-
Affiliations: Department of Anesthesiology, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421002, P.R. China, Cancer Research Institute, Medical College of University of South China, Hengyang, Hunan 421001, P.R. China - Published online on: March 11, 2021 https://doi.org/10.3892/mmr.2021.11986
- Article Number: 347
-
Copyright: © Gong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Piotrowski I, Kulcenty K and Suchorska W: Interplay between inflammation and cancer. Rep Pract Oncol Radiother. 25:422–427. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Beeghly-Fadiel A, Wilson AJ, Keene S, Ramahi M, Xu S, Marnett LJ, Fadare O, Crispens MA and Khabele D: Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors. J Ovarian Res. 11:172018. View Article : Google Scholar : PubMed/NCBI | |
|
Ayiomamitis GD, Notas G, Vasilakaki T, Tsavari A, Vederaki S, Theodosopoulos T, Kouroumalis E and Zaravinos A: Understanding the Interplay between COX-2 and hTERT in colorectal cancer using a multi-omics analysis. Cancers (Basel). 11:15362019. View Article : Google Scholar | |
|
Pollock JK, Greene LM, Nathwani SM, Kinsella P, O'Boyle NM, Meegan MJ and Zisterer DM: Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells. Invest New Drugs. 36:523–535. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gurram B, Zhang S, Li M, Li H, Xie Y, Cui H, Du J, Fan J, Wang J and Peng X: Celecoxib conjugated fluorescent probe for identification and discrimination of cyclooxygenase-2 enzyme in cancer cells. Anal Chem. 90:5187–5193. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
O'Brien J, Hayder H, Zayed Y and Peng C: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 9:4022018. View Article : Google Scholar : PubMed/NCBI | |
|
Esquela-Kerscher A and Slack FJ: Oncomirs microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Ge X, Xu Z and Chen D: Identification of circular RNA-microRNA-messenger RNA regulatory network in hepatocellular carcinoma by integrated analysis. J Gastroenterol Hepatol. 35:157–164. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res. 36:D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kim B, Jeong K and Kim VN: Genome-wide mapping of DROSHA cleavage sites on primary MicroRNAs and noncanonical substrates. Mol Cell. 66:258–269.e5. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
He L and Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Babaei K, Shams S, Keymoradzadeh A, Vahidi S, Hamami P, Khaksar R, Norollahi SE and Samadani AA: An insight of microRNAs performance in carcinogenesis and tumorigenesis; an overview of cancer therapy. Life Sci. 240:1170772020. View Article : Google Scholar : PubMed/NCBI | |
|
Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F and Tan HB: Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 470:126–133. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Moon H, White AC and Borowsky AD: New insights into the functions of Cox-2 in skin and esophageal malignancies. Exp Mol Med. 52:538–547. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Han F, Ren J, Zhang J, Sun Y, Ma F, Liu Z, Yu H, Jia J and Li W: JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression. Oncotarget. 7:38626–38637. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Borchert GL, Surazynski A and Phang JM: Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers. Oncogene. 27:6729–6737. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hashemi Goradel N, Najafi M, Salehi E, Farhood B and Mortezaee K: Cyclooxygenase-2 in cancer: A review. J Cell Physiol. 234:5683–5699. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Montezuma MAP, Fonseca FP, Benites BM, Soares CD, do Amaral-Silva GK, de Almeida OP, Soares FA, Pagano RL and Fregnani ER: COX-2 as a determinant of lower disease-free survival for patients affected by ameloblastoma. Pathol Res Pract. 214:907–913. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Han L, Fang S, Li G, Wang M and Yu R: Total flavonoids suppress lung cancer growth via the COX-2-mediated Wnt/β-catenin signaling pathway. Oncol Lett. 19:1824–1830. 2020.PubMed/NCBI | |
|
Conejo-Garcia JR: Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer. J Clin Invest. 129:3521–3523. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bourn J, Pandey S, Uddin J, Marnett L and Cekanova M: Detection of tyrosine kinase inhibitors-induced COX-2 expression in bladder cancer by fluorocoxib A. Oncotarget. 10:5168–5180. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Shi C, Zeng L, Liu G, Jiang W, Zhang X, Chen S, Guo J, Jian X, Ouyang J, et al: High COX-2 expression in cancer-associated fibiroblasts contributes to poor survival and promotes migration and invasiveness in nasopharyngeal carcinoma. Mol Carcinog. 59:265–280. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu Z, Zhao X, Feng L, Zhang B, Jin L, et al: Andrographolide inhibits breast cancer through suppressing COX-2 expression and angiogenesis via inactivation of p300 signaling and VEGF pathway. J Exp Clin Cancer Res. 37:2482018. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Zhu J, Gou H, Cao D, Jiang M and Hou M: Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol. 28:796–803. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Garrido MP, Hurtado I, Valenzuela-Valderrama M, Salvatierra R, Hernández A, Vega M, Selman A, Quest AFG and Romero C: NGF-enhanced vasculogenic properties of epithelial ovarian cancer cells is reduced by inhibition of the COX-2/PGE2 signaling Axis. Cancers (Basel). 11:19702019. View Article : Google Scholar | |
|
Hosseini F, Mahdian-Shakib A, Jadidi-Niaragh F, Enderami SE, Mohammadi H, Hemmatzadeh M, Mohammed HA, Anissian A, Kokhaei P, Mirshafiey A and Hassannia H: Anti-inflammatory and anti-tumor effects of α-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model. Biomed Pharmacother. 98:793–800. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Janakiraman H, House RP, Talwar S, Courtney SM, Hazard ES, Hardiman G, Mehrotra S, Howe PH, Gangaraju V and Palanisamy V: Repression of caspase-3 and RNA-binding protein HuR cleavage by cyclooxygenase-2 promotes drug resistance in oral squamous cell carcinoma. Oncogene. 36:3137–3148. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Raj V, Bhadauria AS, Singh AK, Kumar U, Rai A, Keshari AK, Kumar P, Kumar D, Maity B, Nath S, et al: Novel 1,3,4-thiadiazoles inhibit colorectal cancer via blockade of IL-6/COX-2 mediated JAK2/STAT3 signals as evidenced through data-based mathematical modeling. Cytokine. 118:144–159. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnamachary B, Stasinopoulos I, Kakkad S, Penet MF, Jacob D, Wildes F, Mironchik Y, Pathak AP, Solaiyappan M and Bhujwalla ZM: Breast cancer cell cyclooxygenase-2 expression alters extracellular matrix structure and function and numbers of cancer associated fibroblasts. Oncotarget. 8:17981–17994. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Esbona K, Yi Y, Saha S, Yu M, Van Doorn RR, Conklin MW, Graham DS, Wisinski KB, Ponik SM, Eliceiri KW, et al: The presence of cyclooxygenase 2, tumor-associated macrophages, and collagen alignment as prognostic markers for invasive breast carcinoma patients. Am J Pathol. 188:559–573. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L and Keely P: COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res. 18:352016. View Article : Google Scholar : PubMed/NCBI | |
|
Hull MA, Cuthbert RJ, Ko CWS, Scott DJ, Cartwright EJ, Hawcroft G, Perry SL, Ingram N, Carr IM, Markham AF, et al: Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the ApcMin/+ mouse model of intestinal tumorigenesis. Sci Rep. 7:60742017. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe Y, Imanishi Y, Ozawa H, Sakamoto K, Fujii R, Shigetomi S, Habu N, Otsuka K, Sato Y, Sekimizu M, et al: Selective EP2 and Cox-2 inhibition suppresses cell migration by reversing epithelial-to-mesenchymal transition and Cox-2 overexpression and E-cadherin downregulation are implicated in neck metastasis of hypopharyngeal cancer. Am J Transl Res. 12:1096–1113. 2020.PubMed/NCBI | |
|
Sorski L, Melamed R, Matzner P, Lavon H, Shaashua L, Rosenne E and Ben-Eliyahu S: Reducing liver metastases of colon cancer in the context of extensive and minor surgeries through beta-adrenoceptors blockade and COX2 inhibition. Brain Behav Immun. 58:91–98. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Soto MS, O'Brien ER, Andreou K, Scrace SF, Zakaria R, Jenkinson MD, O'Neill E and Sibson NR: Disruption of tumour-host communication by downregulation of LFA-1 reduces COX-2 and e-NOS expression and inhibits brain metastasis growth. Oncotarget. 7:52375–52391. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Majumder M, Landman E, Liu L, Hess D and Lala PK: COX-2 elevates oncogenic miR-526b in breast cancer by EP4 activation. Mol Cancer Res. 13:1022–1033. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pan J, Yang Q, Shao J, Zhang L, Ma J, Wang Y, Jiang BH, Leng J and Bai X: Cyclooxygenase-2 induced β1-integrin expression in NSCLC and promoted cell invasion via the EP1/MAPK/E2F-1/FoxC2 signal pathway. Sci Rep. 6:338232016. View Article : Google Scholar : PubMed/NCBI | |
|
Lang S, Picu A, Hofmann T, Andratschke M, Mack B, Moosmann A, Gires O, Tiwari S and Zeidler R: COX-inhibitors relieve the immunosuppressive effect of tumor cells and improve functions of immune effectors. Int J Immunopathol Pharmacol. 19:409–419. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Höing B, Kanaan O, Altenhoff P, Petri R, Thangavelu K, Schlüter A, Lang S, Bankfalvi A and Brandau S: Stromal versus tumoral inflammation differentially contribute to metastasis and poor survival in laryngeal squamous cell carcinoma. Oncotarget. 9:8415–8426. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mortezaee K: Immune escape: A critical hallmark in solid tumors. Life Sci. 258:1181102020. View Article : Google Scholar : PubMed/NCBI | |
|
Miao J, Lu X, Hu Y, Piao C, Wu X, Liu X, Huang C, Wang Y, Li D and Liu J: Prostaglandin E 2 and PD-1 mediated inhibition of antitumor CTL responses in the human tumor microenvironment. Oncotarget. 8:89802–89810. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E and Van den Eynde BJ: Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance. Cancer Immunol Res. 5:695–709. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Moon H, Kim D, Donahue LR and White AC: Phenotypic plasticity of cutaneous squamous cell carcinoma mediated by cyclooxygenase-2. J Invest Dermatol. 140:1665–1669, e1665. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Moon H, Zhu J, Donahue LR, Choi E and White AC: Krt5+/Krt15+ foregut basal progenitors give rise to cyclooxygenase-2-dependent tumours in response to gastric acid stress. Nat Commun. 10:22252019. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang Y, Tian Q, Guan L and Niu SS: The dual role of miR-186 in cancers: Oncomir battling with tumor suppressor miRNA. Front Oncol. 10:2332020. View Article : Google Scholar : PubMed/NCBI | |
|
Bai J, Xu J, Zhao J and Zhang R: LncRNA NBR2 suppresses migration and invasion of colorectal cancer cells by downregulating miRNA-21. Hum Cell. 33:98–103. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Chen J and He G, Xu W and He G: Impact of mirna-21 on survival prognosis in patients with pancreatic cancer: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 99:e220452020. View Article : Google Scholar : PubMed/NCBI | |
|
Bascuñán KA, Pérez-Bravo F, Gaudioso G, Vaira V, Roncoroni L, Elli L, Monguzzi E and Araya M: A miRNA-based blood and mucosal approach for detecting and monitoring celiac disease. Dig Dis Sci. 65:1982–1991. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Irimie AI, Braicu C, Sonea L, Zimta AA, Cojocneanu-Petric R, Tonchev K, Mehterov N, Diudea D, Buduru S and Berindan-Neagoe I: A looking-glass of non-coding RNAs in oral cancer. Int J Mol Sci. 18:26202017. View Article : Google Scholar | |
|
Liu Y, Li H, Zhao C and Jia H: MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma. Mol Cell Biochem. 448:61–69. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pop-Bica C, Pintea S, Cojocneanu-Petric R, Del Sal G, Piazza S, Wu ZH, Alencar AJ, Lossos IS, Berindan-Neagoe I and Calin GA: MiR-181 family-specific behavior in different cancers: a meta-analysis view. Cancer Metastasis Rev. 37:17–32. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ruan K, Fang X and Ouyang G: MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Lett. 285:116–126. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Ørntoft TF, et al: The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 106:366–374. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Aldebasi YH, Rahmani AH, Khan AA and Aly SM: The effect of vascular endothelial growth factor in the progression of bladder cancer and diabetic retinopathy. Int J Clin Exp Med. 6:239–251. 2013.PubMed/NCBI | |
|
Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. Biomed Pharmacother. 122:1096872020. View Article : Google Scholar : PubMed/NCBI | |
|
Stiegelbauer V, Perakis S, Deutsch A, Ling H, Gerger A and Pichler M: MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol. 20:11727–11735. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hao Y, Gu X, Zhao Y, Greene S, Sha W, Smoot DT, Califano J, Wu TC and Pang X: Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila). 4:1073–1083. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Smits M, Nilsson J, Mir SE, van der Stoop PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J, Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, He Z, Ma D, Wang L, Wang YJ, Zong Y, et al: Cyclooxygenase-2, a potential therapeutic target, is regulated by miR-101 in esophageal squamous cell carcinoma. PLoS One. 10:e01406422015. View Article : Google Scholar : PubMed/NCBI | |
|
Lv P, Zhang P, Li X and Chen Y: Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2. Thorac Cancer. 6:778–784. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
He XP, Shao Y, Li XL, Xu W, Chen GS, Sun HH, Xu HC, Xu X, Tang D, Zheng XF, et al: Downregulation of miR-101 in gastric cancer correlates with cyclooxygenase-2 overexpression and tumor growth. FEBS J. 279:4201–4212. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraju GP and El-Rayes BF: Cyclooxygenase-2 in gastrointestinal malignancies. Cancer. 125:1221–1227. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Ding Y, Wu Y and Wang X: Identification of the complex regulatory relationships related to gastric cancer from lncRNA-miRNA-mRNA network. J Cell Biochem. 121:876–887. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G and Li B: Role of miRNA in transformation from normal tissue to colorectal adenoma and cancer. J Cancer Res Ther. 15:278–285. 2019.PubMed/NCBI | |
|
Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N and Akao Y: Decreased expression of microRNA-143 and −145 in human gastric cancers. Oncology. 77:12–21. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wu XL, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, Tian DA and Zhang P: MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. World J Gastroenterol. 19:7758–7765. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yao Q, Gu A, Wang Z and Xue Y: MicroRNA-144 functions as a tumor suppressor in gastric cancer by targeting cyclooxygenase-2. Exp Ther Med. 15:3088–3095. 2018.PubMed/NCBI | |
|
Liu X, Ji Q, Zhang C, Liu X, Liu Y, Liu N, Sui H, Zhou L, Wang S and Li Q: miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models. Sci Rep. 7:71132017. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Li Y, Liu D, Zhang R and Zhang J: miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway. FEBS Lett. 588:3274–3281. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen P, Wang BL, Pan BS and Guo W: MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer Prev. 15:9185–9190. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang D, Li Y, Zhang C, Li X and Yu J: MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX-2 and ALOX5. J Cell Biochem. 119:1755–1766. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty C, Sharma AR, Sharma G and Lee SS: The interplay among miRNAs, major cytokines, and cancer-related inflammation. Mol Ther Nucleic Acids. 20:606–620. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang YM, Kim SY and Seki E: Inflammation and liver cancer: Molecular mechanisms and therapeutic targets. Semin Liver Dis. 39:26–42. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Agra Andrieu N, Motiño O, Mayoral R, Llorente Izquierdo C, Fernández-Alvarez A, Boscá L, Casado M and Martín-Sanz P: Cyclooxygenase-2 is a target of microRNA-16 in human hepatoma cells. PLoS One. 7:e509352012. View Article : Google Scholar : PubMed/NCBI | |
|
Jia H, Wang H, Yao Y, Wang C and Li P: miR-136 inhibits malignant progression of hepatocellular carcinoma cells by targeting cyclooxygenase 2. Oncol Res. 26:967–976. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Lu X, Zou X, Jiang Y, Yao J, Liu H, Ni B and Ma H: COX-2 rs5275 and rs689466 polymorphism and risk of lung cancer: A PRISMA-compliant meta-analysis. Medicine (Baltimore). 97:e118592018. View Article : Google Scholar : PubMed/NCBI | |
|
Zago M, Rico de Souza A, Hecht E, Rousseau S, Hamid Q, Eidelman DH and Baglole CJ: The NF-κB family member RelB regulates microRNA miR-146a to suppress cigarette smoke-induced COX-2 protein expression in lung fibroblasts. Toxicol Lett. 226:107–116. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xia M, Duan ML, Tong JH and Xu JG: MiR-26b suppresses tumor cell proliferation, migration and invasion by directly targeting COX-2 in lung cancer. Eur Rev Med Pharmacol Sci. 19:4728–4737. 2015.PubMed/NCBI | |
|
Kwon Y, Kim Y, Eom S, Kim M, Park D, Kim H, Noh K, Lee H, Lee YS, Choe J, et al: MicroRNA-26a/-26b-COX-2-MIP-2 loop regulates allergic inflammation and allergic inflammation-promoted enhanced tumorigenic and metastatic potential of cancer cells. J Biol Chem. 290:14245–14266. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu C, Li X, Zhang D, Xu B, Hu W, Zheng X, Zhu D, Zhou Q, Jiang J and Wu C: IL-1β-mediated Up-regulation of WT1D via miR-144-3p and their synergistic effect with NF-κB/COX-2/HIF-1α pathway on cell proliferation in LUAD. Cell Physiol Biochem. 48:2493–2502. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li B, Lu Y, Yu L, Han X, Wang H, Mao J, Shen J, Wang B, Tang J, Li C and Song B: miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF-κB/COX-2 activation. Chem Biol Interact. 277:33–42. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, Hess D and Lala PK: COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Sci Rep. 8:3272018. View Article : Google Scholar : PubMed/NCBI | |
|
Liao H, Zhou Q, Gu Y, Duan T and Feng Y: Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI | |
|
Lai Y, Zhang X, Zhang Z, Shu Y, Luo X, Yang Y, Wang X, Yang G, Li L and Feng Y: The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells. Int J Oncol. 42:776–784. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Y and Wu Z: MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2. Gene. 658:63–69. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chen ZG, Zheng CY, Cai WQ, Li DW, Ye FY, Zhou J, Wu R and Yang K: miR-26b mimic inhibits glioma proliferation in vitro and in vivo suppressing COX-2 expression. Oncol Res. 27:147–155. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL and Shields JA: Retinoblastoma management: Advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, He J and Zhang L: The down-regulation of microRNA-137 contributes to the up-regulation of retinoblastoma cell proliferation and invasion by regulating COX-2/PGE2 signaling. Biomed Pharmacother. 106:35–42. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Q, Zhang K, Wang X, Liu X and Zhang Z: Expression of transcription factors snail, slug, and twist in human bladder carcinoma. J Exp Clin Cancer Res. 29:1192010. View Article : Google Scholar : PubMed/NCBI | |
|
Song T, Zhang X, Wang C, Wu Y, Dong J, Gao J, Cai W and Hong B: Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev. 12:9292011.PubMed/NCBI | |
|
Xu L, Shen B, Chen T and Dong P: miR-203 is involved in the laryngeal carcinoma pathogenesis via targeting VEGFA and Cox-2. Onco Targets Ther. 9:4629–4637. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K and Miltyk W: Celecoxib in cancer therapy and prevention-review. Curr Drug Targets. 20:302–315. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS: Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol. 21:635–637. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Strillacci A, Griffoni C, Valerii MC, Lazzarini G, Tomasi V and Spisni E: RNAi-based strategies for cyclooxygenase-2 inhibition in cancer. J Biomed Biotechnol. 2010:8280452010. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Wu Y, Zhou Z, Huang M, Deng W, Wang Y, Zhou X, Chen L, Li Y, Zeng T, et al: Celecoxib inhibits the epithelial-to-mesenchymal transition in bladder cancer via the miRNA-145/TGFBR2/Smad3 axis. Int J Mol Med. 44:683–693. 2019.PubMed/NCBI | |
|
Ghose J and Bhattacharyya NP: Transcriptional regulation of microRNA-100, −146a, and −150 genes by p53 and NFκB p65/RelA in mouse striatal STHdh(Q7)/Hdh(Q7) cells and human cervical carcinoma HeLa cells. RNA Biol. 12:457–477. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
DA Costa RM, Bastos MM, Medeiros R and Oliveira PA: The NFkB signaling pathway in papillomavirus-induced lesions: Friend or foe? Anticancer Res. 36:2073–2083. 2016.PubMed/NCBI | |
|
DA Costa RMG, Araújo R, Santos JMO, Fernandes M, Neto T, Sousa H, Ribeiro J, Bastos MMSM, Oliveira PA, Carmo D, et al: Regulation of miRNA-146a and miRNA-150 Levels by celecoxib in premalignant lesions of K14-HPV16 mice. Anticancer Res. 37:2913–2918. 2017.PubMed/NCBI | |
|
Saito Y, Suzuki H, Imaeda H, Matsuzaki J, Hirata K, Tsugawa H, Hibino S, Kanai Y, Saito H and Hibi T: The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer. 132:1751–1760. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Mott JL, Kobayashi S, Bronk SF and Gores GJ: mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene. 26:6133–6140. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hunter S, Nault B, Ugwuagbo KC, Maiti S and Majumder M: Chemicall induced hypoxia enhances miRNA functions in breast cancer. Cancers (Basel). 12:20082020. View Article : Google Scholar | |
|
Najafi M, Farhood B, Mortezaee K, Kharazinejad E, Majidpoor J and Ahadi R: Hypoxia in solid tumors: A key promoter of cancer stem cell (CSC) resistance. J Cancer Res Clin Oncol. 146:19–31. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong W, Li WH, Jiang YX, Liu S, Ai YQ, Liu R, Chang L, Zhang M, Wang XL, Bai H, et al: Parecoxib: An enhancer of radiation therapy for colorectal cancer. Asian Pac J Cancer Prev. 16:627–633. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zagani R, Hamzaoui N, Cacheux W, de Reyniès A, Terris B, Chaussade S, Romagnolo B, Perret C and Lamarque D: Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers. Gastroenterology. 137:1358–1366.e1-3. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Li LY, Xiao J, Liu Q and Xia K: Parecoxib inhibits glioblastoma cell proliferation, migration and invasion by up-regulating miRNA-29c. Biol Open. 6:311–316. 2016. View Article : Google Scholar | |
|
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, et al: Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 375:2519–2529. 2016. View Article : Google Scholar : PubMed/NCBI |
